Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 182

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Disease Control Rate at 8 Weeks Predicts Clinical Benefit in Advanced Non–Small-Cell Lung Cancer: Results From Southwest Oncology Group Randomized Trials

Lara, Primo N., Redman, Mary W., Kelly, Karen, Edelman, Martin J., Williamson, Stephen K., Crowley, John J., Gandara, David R.·2008·Journal of Clinical Oncology

Abstract

Purpose: Tumor shrinkage categorized as complete response (CR) or partial response (PR) is a fundamental efficacy measure for new cancer treatments and often considered a surrogate for overall survival. However, for any given treatment, many more patients typically achieve stable disease (SD) or have progressive disease (PD) than achieve response. We hypothesized that PD (or its converse, disease control rate [DCR], consisting of CR, PR, SD) is a stronger predictor of survival than response alone in advanced non–small-cell lung cancer (NSCLC), and that this determination might be assessable early on during therapy. Patients and Methods: Data from 984 NSCLC patients entered onto three randomized Southwest Oncology Group trials of platinum-based chemotherapy were pooled and subjected to Landmark survival analysis. Patients were categorized according to proportions alive at weeks 8, 14, and 20 after registration, as well as response status. Elements were fitted into a Cox proportional hazards model. Results: Tumor response (CR, PR) was seen in 260 patients (27%). Median time to response, time to progression, and survival time were 2.0, 4.3 and 8.9 months, respectively. Median survival times among patients with CR/PR, SD, or PD were 13.5, 8.4, and 3.1 months, respectively. Of 892 patients alive at week 8, DCR was 62%. Although CR/PR at week 8 was associated with longer survival (hazard ratio [HR] = 0.61; P < .001), DCR was superior in predicting survival (HR = 0.45; P < .0001). Conclusion: DCR at week 8 is a more powerful predictor of subsequent survival than is the traditional tumor response rate in advanced NSCLC and provides an early assessment of subsequent outcome.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2007.13.0344

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 15

  1. 10.1016/S0959-8049(02)00182-X · DOI
  2. 10.1200/JCO.2000.18.19.3390 · DOI · Paper page
  3. 10.1200/JCO.1990.8.9.1556 · DOI · Paper page
  4. 10.1200/JCO.1993.11.5.873 · DOI
  5. 10.1016/S0197-2456(83)80011-7 · doi:10.1016/s0197-2456(83)80011-7
  6. 10.1016/0021-9681(60)90137-5 · DOI · Paper page
  7. 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6 · DOI · Paper page
  8. Green S, Weiss GR: Southwest Oncology Group standard response criteria, endpoint definitions, and toxicity criteria. Invest New Drugs 10:259,1992-253, · DOI · Paper page
  9. 10.1093/jnci/92.3.205 · DOI · Paper page
  10. 10.1200/JCO.2003.01.144 · DOI · Paper page
  11. 10.1056/NEJMc052173 · DOI
  12. 10.1200/JCO.2001.19.13.3210 · DOI · Paper page
  13. 10.1158/1078-0432.CCR-04-0002 · DOI
  14. 10.1200/JCO.2005.01.3771 · DOI
  15. 10.1200/JCO.1983.1.11.710 · DOI · Paper page

Cited by

See all 182

Metadata

Authors
Lara, P. N., Redman, M. W., Kelly, K., Edelman, M. J., Williamson, S. K., Crowley, J. J., & Gandara, D. R.
Venue
Journal of Clinical Oncology
Published
2008-01-20
Volume
26
Issue
3
Pages
463-467
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2099173339
Cited by
182
References
1
FWCI
18.64
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Disease Control Rate at 8 Weeks Predicts Clinical Benefit in Advanced Non–Small-Cell Lung Cancer: Results From Southwest Oncology Group Randomized Trials. https://app.cochat.ai/papers/10.1200/jco.2007.13.0344
The paper
Lara, P. N., Redman, M. W., Kelly, K., Edelman, M. J., Williamson, S. K., Crowley, J. J., & Gandara, D. R. (2008). Disease Control Rate at 8 Weeks Predicts Clinical Benefit in Advanced Non–Small-Cell Lung Cancer: Results From Southwest Oncology Group Randomized Trials. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2007.13.0344

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.